Congratulations to the #ImmuneWalk team on the dosing of first 2 participants in the PointGuard clinical trial evaluating IW-601! IW-601 is a proprietary monoclonal antibody targeting a novel adhesion checkpoint, providing a unique pathway to block #monocytes ability to get into inflammatory tissue. The program has potential applications in a broad range of #immune and #inflammatory (#I&I) applications, and has demonstrated robust effects in preclinical models and ex-vivo patient blood samples in #MultipleScleroris, #RheumatoidArthritis, #Crohns, #UlcerativeColitis, #NASH, and #Uveitis. The clinical trial will evaluate the safety, pharmacodynamics, and pharmacokinetics of our unique approach to inflammatory disease in approximately 50 subjects. Data from single ascending doses are expected by YE24, with multiple ascending dose data available in 2H25. Follow to join us on our journey and reach out if you’d like to hear more about this exciting program! #inflammation #immunology #checkpoint #adhesion #first-in-man #ClinicalTrial #Biotechnology #biotech #HealthcareInnovation #SeriesA
ImmuneWalk Therapeutics
Biotechnology Research
Pearl River, New York 80 followers
Clinical-stage company focused on development of novel therapies for highly prevalent and rare inflammatory indications
About us
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Pearl River, New York
- Type
- Privately Held
- Founded
- 2023
- Specialties
- • Stopping Disease in its Tracks with Precision Monocyte Targeting Technology, • Potential for Highly Prevalent and Rare Inflammatory Indications, and • New Biology Translated to Innovative Therapy
Locations
-
Primary
Get directions
1 Blue Hill Plaza
Pearl River, New York 10965, US
Employees at ImmuneWalk Therapeutics
-
Sam Backenroth
Managing Director, CFO Leadership at LS Associates, Co-Founder at ImmuneWalk Therapeutics
-
Dror Harats
CEO at ImmuneWalk Therapeutics
-
Tami Rachmilewitz
Medical Director | Clinical Development | Clinical Research Physician
-
Oshrat Propheta meiran
Research and Development | Bio-Pharmaceutical | Molecular and Cell Biology | Biochemistry | Flow Cytometry | Immunology and Cell Base Assay
Updates
-
Productive discussion by Dr. Dror Harats, CEO & colleagues at the Longwood Healthcare Leaders Spring MIT conference in Cambridge, MA.
Productive discussion on managing the runway with #biotech CEOs Paul Peter Tak, MD PhD FMedSci Candel Tx, Anna Kazanchyan, M.D. Saghmos Therapeutics, Dror Harats ImmuneWalk Therapeutics, Brendan Smith Doppler Bio & Pratik Shah Design Therapeutics #longwoodhealthcareleaders
-
-
We are excited to announce the founding of ImmuneWalk Therapeutics, a clinical stage I&I (#Inflammation & #Immunology) company stopping monocytes in their tracks to treat chronic inflammatory disease. We recently completed an institutional seed funding round and are ramping up. More details to follow! #monocytes #biotech #seriesA #therapy #startupnation
-